Publications by authors named "D Rosmarin"
Use of Complementary and Integrative Medicine Among Low-Income Persons With Mental Health Disorders.
Mayo Clin Proc Innov Qual Outcomes
February 2025
Objective: To evaluate the use of complementary and integrative medicine (CIM) among a low-income population with mental health diagnoses and to assess differences in social determinants of health (SDOH) on the basis of CIM use.
Patients And Methods: We surveyed patients with mental health diagnoses and/or substance use disorders during outpatient evaluations between August 11, 2020, and November 18, 2021, at a community behavioral health center in Rochester, MN. We measured knowledge of current CIM, interest in future use of CIM, and SDOH.
Background: Lebrikizumab demonstrated statistically significant improvements in patients with moderate-to-severe atopic dermatitis at week 16 with a durable response up to week 52.
Objective: To investigate the efficacy of lebrikizumab-treated patients at 52 weeks who did not achieve the ADvocate1 and ADvocate2 protocol-defined response criteria (≥75% improvement in the Eczema Area and Severity Index [EASI 75] or Investigator Global Assessment [IGA] 0/1 with ≥2-point improvement without rescue medication) after 16 weeks.
Methods: This analysis includes observed data for patients who received lebrikizumab every 2 weeks during the induction period, did not achieve the protocol-defined response, and subsequently received open-label lebrikizumab treatment.
Background: Psoriasis is a chronic inflammatory skin disease often associated with obesity. Psoriasis therapies may be less effective in patients with obese. The purpose of this expert consensus panel is to evaluate the relationship between obesity and efficacy of psoriasis therapies, thereby optimizing patient care.
View Article and Find Full Text PDFArticle Synopsis
- Upadacitinib shows faster and more effective results in reducing atopic dermatitis severity compared to dupilumab over 24 weeks, based on the Eczema Area and Severity Index (EASI).
- In a study, patients treated with upadacitinib achieved greater skin clearance rates of ≥75%, ≥90%, and 100% in all analyzed body regions earlier than those on dupilumab.
- Patient feedback indicated that those on upadacitinib reported significantly better outcomes for symptoms in the head and neck area as soon as week 1.